Advagene Biotechnology Co., Ltd. completed the detoxification LT (LTh(αK)) adjuvant technology platform of the Technology Transfer Consortium Biotechnology Development Center in early 2014. Its products include: nasal spray influenza vaccine (LT-Flu), respiratory allergy treatment vaccine, including rhinitis and athsma (LT-Allergy ), Other vaccines, etc., have complete material patents, application patents and process patents, and have obtained patent licenses from Taiwan, China, the United States, Europe, Japan, Russia, Australia, Canada and other countries.

"Application and platform technology of detoxified enterotoxin protein LT (LTh(αK)) adjuvant" won the "Annual Innovation Award" of the Outstanding Biotechnology Industry Award of the Republic of China Bioindustry Development Association in 2014. Among them, the nasal spray influenza vaccine (LT-Flu) has been The second phase of human clinical trials has been completed to confirm safety and effectiveness. The data show that the nasal spray not only induces an antiviral IgG response, but also produces an antiviral mucosal IgA response, which can protect the first-line mucosal tissues of human infection. The LT-Flu nasal spray formulation is currently planned for Phase III clinical trials. In the future, in addition to the general public being able to avoid the fear of injections during vaccination, it will also provide better protection for the elderly and medical workers, and strive for more than 3 billion US dollars in annual sales The amount of flu vaccine market.
In addition, it is applied to the treatment of allergic respiratory diseases. It has application patents in Taiwan, the United States, Japan and other countries. It is expected to replace or reduce the use of steroids and other drugs. It can benefit about hundreds of millions of patients with respiratory allergic diseases worldwide and alleviate hay fever in the United States and Asia. The allergy medication needs of dust mite allergy patients, and regulates the immune response of autoimmune cells to allergen stimulation. The phase I/II human clinical trials of  LTh(αK) used in the treatment of dust mite allergic rhinitis is completed in 2021. And phase II clinical trials of eosinophilic asthma treatment is initiated in 2023.

COVID-19 immunotherapy is another application of LTh(αK) platform technology. The phase II trial in Taiwan and the phase II/III in Indonesia were initiated in 2021.